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ABSTRACT  (245 words) 
Purpose: 
18
F-fluorodeoxyglucose (FDG) PET/CT and MRI are used for detecting liver 
metastases from uveal melanoma. The introduction of new treatment options in clinical 
trials might benefit from early response assessment. Here, we determined the value of 
FDG PET/CT with respect to MRI at diagnosis and its potential for monitoring therapy. 
Material and Methods: Ten patients with biopsy-proven liver metastases of uveal mel-
anoma enrolled in a randomized phase III trial (NCT00110123) underwent both FDG-
PET coupled with unenhanced CT and Gadolinium-DTPA-enhanced liver MRI within 4 
weeks. FDG PET and MRI were evaluated blindly and then compared using the ratio of 
lesion to normal liver parenchyma PET-derived standardized uptake value (SUV). The 
influence of lesion size and response to chemotherapy were studied.  
Results: Overall, 108 liver lesions were seen: 34 (31%) on both modalities (1–18 
lesions/patient), 4 (4%) by PET/CT only and 70 (65%) by MRI only. SUV correlated 
with MRI lesion size (r=0.81, P<0.0001). PET/CT detected 26/33 (79%) MRI lesions 
≥1.2cm, while it detected only 8/71 (11%) lesions <1.2-cm (P<0.0001). MRI lesions 
without PET correspondence were small (0.6±0.2cm vs. 2.1±1.1cm, P<0.0001). During 
follow-up (6 patients, 30 lesions), the ratio lesion-to-normal-liver SUV diminished in 
size-stable lesions (1.90±0.64 to 1.46±0.50, P<0.0001), while it increased in enlarging 
lesions (1.56±0.40 to 1.99±0.56, P=0.032). 
Conclusion: MRI outweighs PET/CT for detecting small liver metastases. However, 
PET/CT detected at least one liver metastasis per patient and changes in FDG uptake 
not related to size change, suggesting a role in assessing early therapy response.  
Keywords: Uveal Melanoma; PET/CT; FDG; MRI; Liver Metastasis. 
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INTRODUCTION 
Uveal melanoma is the most common primary intraocular malignancy in Caucasians, 
representing 70 % of all ocular tumors [1]. Median age at presentation is about 60 years 
and reported annual incidence ranges from 5.3–10.9 cases per million in the USA and 
2–8 cases per million in Europe [2, 3]. Due to the lack of lymphatics in the eye, meta-
static spread of uveal melanoma is exclusively hematogenous, predominantly to the 
liver (≥95% of metastatic patients) [4]. Around 1% of patients have demonstrable liver 
metastases at presentation, and up to 50% will ultimately develop hepatic metastases 
within 10-15 years, suggesting the presence of subclinical disease at the time of initial 
diagnosis [1]. The mechanisms for this liver tropism is not yet understood [4]. Other 
less common sites of metastasis are lungs, bones, skin, lymph nodes, pancreas, heart, 
spleen, adrenal glands, gastro-intestinal tract, kidneys, ovaries and thyroid. Several 
clinical, histopathological and cytogenetic characteristics are associated with poor 
prognosis including chromosomal abnormalities, the most important of which are 
monosomy 3, isochromosome 6p, trisomy 8, and isochromosome 8q [5].  
Currently, there are no effective treatments to prevent, delay or treat liver me-
tastases of uveal melanoma and median survival after diagnosis of liver metastasis is 2–
7 months in historical series [6]. Several regional therapies are clinically used or under 
investigation in clinical trials to control liver progression, such as hepatic arterial chem-
otherapy, chemoembolization [6], radioembolization [7], thermoablation [8] or targeted 
therapies showing potential benefit on overall survival or response rate, even without 
objective tumor response [4, 9]. For instance, using intra-arterial hepatic fotemustine 
chemotherapy, median survival of up to 15 months has been observed in association 
with a 36% response rate and 33% survival rate at 2 years [10].  
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Positron emission tomography (PET) with 
18
F-fluorodeoxyglucose (FDG) is a 
sensitive and an accurate method for the detection of metastases from cutaneous mela-
noma. Of limited value for the diagnosis of ocular melanoma, it was found to be sensi-
tive for the detection of hepatic and extra-hepatic metastases [11-14]. Servois and co-
workers compared the performance of FDG-PET and MRI for staging liver metastasis 
and concluded that MRI was superior to FDG-PET [15], but the respective value of 
FDG PET and MRI imaging have not been fully assessed in intra-patient comparison 
for the diagnosis and monitoring of liver metastasis from uveal melanoma [12]. Tumor 
uptake of FDG is highly reproducible and decrease is known to occur before change in 
size [16]. Whether this remains true for liver metastases from uveal melanoma is not 
known.  
Early diagnosis of liver metastasis may be important for therapeutic manage-
ment [17]. Furthermore early response assessment may benefit the introduction of new 
treatment options as key oncogenic processes leading to uveal melanoma have been 
recently identified [18]. Our purpose was to determine the respective value of FDG PET 
and MRI imaging in patients with liver metastases of uveal melanoma.  
 
 
METHODS  
Patient Selection 
From 2004 to 2008, 10 patients with known uveal melanoma and at least one histologi-
cally-proven liver metastasis were enrolled in a randomized phase III multicentric trial 
from the Uveal Melanoma Group of the European Organization for Research and 
Treatment of Cancer (EORTC) comparing the effect on overall survival of hepatic intra-
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arterial to systemic intravenous administration of fotemustine in patients with liver me-
tastases from uveal melanoma (EORTC-18021, NCT00110123). This trial was initiated 
after a phase II trial at our center showed evidence for improved survival after intra-ar-
terial hepatic fotemustine chemotherapy [19]. Eligibility criteria were age ≥18 years, 
surgically incurable or unresectable disease and no extrahepatic metastases; exclusion 
criteria were previous chemo or radiotherapy, abnormal hematopoiesis, abnormal kid-
ney or liver function, uncontrolled angina pectoris, myocardial infarction <6 months, 
intracranial hypertension, other severe cardiac disease, other malignancy <5 years. Pa-
tients not having recovered from prior major surgery or with performance status not 
WHO >2 were also excluded.  The protocol was approved by the local ethics committee 
and the Swiss regulatory authorities, and patients signed informed consent forms before 
inclusion.  
At our center, this protocol included an imaging study comparing MRI imaging 
and FDG PET that is presented here. Ten patients (6 women, 4 men; 20–74 years at 
diagnosis) were studied by MRI and PET/CT within 4 weeks (range 0–25 days). Of 
them, 6 patients were studied at baseline and 4 early during chemo-induction (after 3–4 
cycles of fotemustine). During follow-up, a subgroup of 6 patients repeated both 
PET/CT and MRI imaging studies within 4 weeks after a variable time on therapy (7–28 
weeks).   
 
MRI 
Abdominal MRI images were acquired on a 1.5T (n=5) and 3T (n=5) scanner 
(Symphony, Siemens Healthcare, Erlangen, Germany) with a maximum gradient 
strength of 40 mT/m using a 4-channel phased-array body coil with a 35×25-cm FOV. 
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Bandwidth was 1346 Hz. The liver protocol encompassed a breath-hold, T2-weighted 
transverse half-Fourier single-shot turbo spin echo sequence (HASTE, repetition 
time/echo time=1100ms/59ms, echo train length=256, matrix=256×148, slab thick-
ness/gap=3mm/0.9mm), a T1-weighted transverse spoiled gradient-echo (GE) sequence 
(in-phase: 167/4.8, out-phase: 167/2.4, 256×134, 6/2, flip angle 70°), a respiratory-trig-
gered T2-weighted transverse fat-suppressed fast spin echo sequence (6361.3/121, echo 
train length=23, 512×188, 6/1.8) and a breath-hold T1-weighted transverse fat-sup-
pressed GE sequences (VIBE, 3.7/1.6, 256×192, 4/0.8, flip angle 12°, 1 NEX). The lat-
ter was performed before and after intravenous Gd-DTPA injection (arterial, portove-
nous, and equilibrium phases; 0.1mmol/kg Omniscan, GE Healthcare). Liver lesions 
were considered suspicious for metastases when presenting a short T1 pattern (high sig-
nal intensity) without injection, an arterial Gd-DPTA enhancement and a short T2 pat-
tern (low signal intensity) as compared to adjacent normal liver; solitary lesions with 
short T1 pattern and a long T2 pattern were also considered as suspicious [20].  
 
FDG PET/CT 
Whole-body PET/CT (Discovery LS scanner, GE Medical System) was acquired 67±15 
min after intravenous bolus injection of FDG (5 MBq/kg) using standard PET/CT ac-
quisition protocols. Patients had been fasting for ≥6 hours and blood glucose at injection 
was <8.3mmol/L. Attenuation correction was performed using an unenhanced CT (140 
keV, 80 mA, 0.8s per rotation, table speed of 15 mm/rotation, slice thickness 5mm). 
Liver lesions were considered suspicious for metastases when FDG uptake was focally 
increased compared to surrounding liver on at least 2 consecutive 5-mm slices.  
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Image Analysis 
An experienced radiologist evaluated the MRI images and an experienced nuclear 
medicine specialist evaluated the PET images. Each reader was blinded to the results of 
the other modality. For MR, hepatic lesions were numbered, evaluated and their largest 
diameter measured. For each suspicious liver lesion, maximal standardized uptake 
values (SUV) corrected for body weight were obtained. To facilitate result comparison 
with other PET centers, we expressed the lesion SUV normalized to normal liver 
parenchyma SUV (“lesion-to-liver SUV ratio”) by dividing the lesion SUV by liver 
SUV averaged in a volume of ≥27 cm3 in a region with uniform activity on PET distant 
from areas with abnormally increased or decreased FDG uptake. In a second reading, 
MRI and PET images were subsequently compared to each other to classify each lesion 
as being detected by both (MR+PET) or a single modality (MRI or PET). The 
intrinsically low resolution of PET scanners and the 3-D voxel sampling contribute to 
the “partial volume effect”, which significantly diminishes the apparent SUV in lesions 
smaller than twice the PET scanner resolution [21]. Therefore, referring to the known 
spatial resolution of our scanner of about 6 mm [22], a subgroup analysis was 
performed according to lesion size <1.2 and ≥1.2 cm diameter.  
 
Statistical Analysis 
Results are presented as mean ± standard deviation (SD), if not specified otherwise. 
Group comparisons were made using unpaired Student’s t-tests for continuous variables 
and the χ2-test for categorical variables. Lesion changes from baseline to follow-up used 
paired Student’s t-test, and associations were sought using Pearson’s correlations. Sig-
nificance was considered for P values <0.05.  
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RESULTS 
Patient Characteristics 
Table 1 summarizes patient and tumor characteristics: no patient presented with a T1 
tumor, 1 with a T2 (10%), 7 with a T3 (70%) and 2 with a T4 (20%) tumor, according 
to the TNM-AJCC (American Joint Cancer Committee) classification [23] and three 
patients already had liver metastasis at primary diagnosis (M1). The median interval 
between the primary diagnosis of uveal melanoma and the detection of hepatic metasta-
sis was 3.0 years (range: 0–10 years). No significant correlation was found between 
SUV on one hand and the total number of lesions, tumor height, largest basal diameter 
or TNM-AJCC classification on the other hand (all P>0.44).  
 
Lesion Detection According Imaging Modality 
Overall, 108 suspicious liver lesions were seen by MRI or PET (Table 2). Of these le-
sions, 34 (31%) were seen on both PET and MRI imaging, 4 (4%) only on PET and 70 
(65%) only on MRI imaging among which 41 were seen in one patient (Figure 1 and 
Figure 2). On a per patient basis, at least one liver metastasis (range 1–18) was detected 
with PET in all patients.  
 
Influence of Lesion Size 
As expected, MRI more often detected small-sized lesions, while most lesions ≥1.2 cm 
could be seen on both modalities. Twenty-six out of 33 (79%) lesions ≥1.2 cm on MRI 
imaging were visualized by PET, while this was the case for only 8 out of 71 (11%) 
lesions <1.2 cm (P<0.0001). Moreover, lesions <1.2 cm had significantly lower SUV 
than larger ≥1.2 cm lesions (3.1±0.5 vs. 4.7±1.8 g/mL, P<0.0001) (Figure 3).  
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FDG PET Standardized Uptake Value 
For lesions detected by both modalities, there was a strong correlation between SUV 
(SUV [g/mL]= 2.9 + 1.06 · MRI size [cm], r = 0.76, P<0.0001), as well as between the 
lesion-to-liver SUV ratio (r = 0.81, P<0.0001) and MRI lesion size (Figure 4). Of note, 
there were 8 subcentimetric lesions detected by PET with SUV significantly increased 
above liver background (3.8±0.5g/mL vs. 3.0±0.4g/mL, P<0.0001) (Figure 4). PET 
lesions with no corresponding MRI lesion presented significantly elevated SUV as 
compared to liver background (4.0±0.5g/mL vs. 3.0±0.4g/mL, P<0.0001) (Figure 5). 
MRI lesions without corresponding PET lesion were significantly smaller (0.6±0.2cm 
vs. 2.1±1.1cm, P<0.0001) (Figure 6).  
 
Lesion Monitoring During Chemotherapy 
Median time between baseline and follow-up imaging was 2.6 months (range 1.5–6.5) 
in the group of 6 patients imaged twice (n=30 lesions in total). As any change in lesion 
size can influence the measured SUV, a subgroup analysis was performed for lesions 
detected on both MRI and PET/CT according to change in lesion size (no significant 
change in size vs. increase in MR-measured largest lesion diameter). The mean SUV of 
liver did not change significantly from baseline to follow-up (2.93±0.46 vs. 2.81±0.25, 
P=0.7). In 5 patients, lesion size (26 lesions) did not change significantly, while 1 
patient (4 lesions) progressed rapidly after 3.9 months, as illustrated in Figure 7. In 
stable lesions (n=26), lesion-to-liver SUV ratio significantly decreased (from 1.90±0.64 
to 1.46±0.50, P<0.0001), while in growing lesions (n=4) lesion-to-liver SUV ratio 
increased (1.56±0.40 to 1.99±0.56, P=0.032).  
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DISCUSSION 
Our study on 10 patients with hepatic metastases from uveal melanoma, totaling over 
100 liver lesions observed on MRI and PET, only 31% of the secondary lesions were 
seen on both modalities whereas most lesions inferior to 1 cm were missed on FDG-
PET. Our data therefore confirm the findings of Servois [15], showing that MRI out-
weighs PET/CT performance for detecting small-sized liver metastases. In consequence, 
MRI appears to be the preferred method for evaluating number and topography of liver 
metastases potentially treatable by local therapy such as surgery, radiofrequency abla-
tion, chemo- or radioembolization. The partial volume effect and artifacts from respira-
tory movements during acquisition prevented detection of most small sized metastases. 
Nevertheless, a few infracentimetric lesions (11%) expressed increased FDG uptake. 
When considering larger sizes (≥1.2 cm), 79% of the lesions were visualized by both 
modalities. On a per-patient basis, FDG-PET proved to be a sensitive investigation, as it 
detected the presence of at least one liver metastasis in every patient of our population. 
This allowed observing changes in the metabolic activity of lesions between baseline 
and follow-up examinations, even in the absence of a change in lesion size on MRI. 
Our study compared MRI imaging to FDG PET in the same patient. Francken et 
al. evaluated the detectability of liver metastasis by PET in a cohort of 22 patients, 
which showed a high sensitivity (10/10), a moderate specificity (67%) and positive and 
negative predictive values of 88% and 100% respectively [13]. They concluded that 
FDG-PET was particularly useful in the detection of isolated, potentially resectable 
liver metastases. The present work does not confirm these initial results, as many more 
liver lesions were detected by MRI imaging alone (PET detection rate 33%) whereas 
only 4 lesions were shown by FDG-PET and not by MRI. These lesions were of limited 
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extension (<3 pixels or <1.2cm) and of unknown origin (no histopathological proof was 
available, as it was deemed not clinically necessary for patient management). Thus an 
artifact at PET or a false negative MRI cannot be excluded. MRI should therefore be 
considered the method of choice for detecting liver metastases of uveal melanoma and 
characterizing liver involvement potentially amenable to local therapy. Our findings are 
in line with recent results by Strobel et al. showing limited value of FDG PET in the 
detection of liver metastasis from uveal melanoma as compared to cutaneous melanoma, 
with a PET detection rate of only 41% (11/27 metastases) [24].  
Importantly, serial PET was able to detect short-term changes in the metabolic 
activity of lesions despite the absence of size change. This has significant implications 
for the early assessment of therapy response and FDG PET assessment of metastases 
has been proposed both as a surrogate marker of treatment response and as a prognostic 
factor for overall survival [25]. Identifying responders and non-responders might im-
prove clinical management in term of side effects and costs [26].  
Baseline SUV was found to be proportional to MRI size, including lesions with 
dimensions well above those where the partial volume effect is no longer expected to 
play a role. In fact, larger SUV values reflect increased rate of glycolysis and have been 
strongly associated with increased tumor aggressiveness and poorer outcome in a num-
ber of cancers such as lung cancer, esophageal cancer or thyroid carcinoma [25, 27]. 
Whether baseline SUV remains an independent prognostic marker in addition to the 
largest dimension of liver metastases needs to be verified in an outcome study following 
published guidelines [28]. 
Obviously, the small size and heterogeneity of our patient population does not 
allow to evaluate the effect of treatment response according to the administration route 
12 
 
or chemotherapeutic regimen, which is the aim of the multicentric EORTC-18021 
study, but with over 100 lesions, comparisons between MRI and PET can be considered 
valid. Four patients had already started chemotherapy at first PET, which may diminish 
PET sensitivity. Another potential limitation is that the diagnosis of metastatic liver 
lesions was based on their characteristic MRI appearance, as it is obviously not possible 
to biopsy all liver lesions. Thus, false positive lesions at MRI cannot be excluded, but 
the combination of T1- and T2-weighting, and behavior after Gd-DTPA injection in-
crease specificity. For a few patients, a dual-phase PET/CT was performed with a late 
phase taken after ≥90 min, which seemed to improve lesion detectability by increasing 
lesion SUV and lesion-to-liver SUV ratio (data not shown); delayed FDG-PET acquisi-
tion might therefore improve the detection of small metastases, as has been demon-
strated for several other tumors as well as primary uveal melanomas [14]. Diffusion-
weighted MRI was not performed in this study, but might be valuable in assessing re-
sponse to therapy, if preliminary results showing treatment related changes in the appar-
ent diffusion coefficient are confirmed [29]. Finally, our pilot study was not designed to 
determine the predictive value of PET or MRI for therapy response. 
 
 
CONCLUSION: 
In this pilot study, MRI outweighs FDG PET performance for detecting small-sized 
liver metastases and is therefore the preferred method for diagnosing the number and 
the topography of liver metastases. However, PET/CT showed decreased FDG uptake in 
absence of MRI change under chemotherapy and increased FDG uptake in lesions in-
creasing in size at follow-up suggesting a possible role for monitoring treatment re-
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sponse. This underlines the need of determining the value of FDG-PET/CT in predicting 
long-term response to therapy in patients with liver metastases from uveal melanoma in 
a prospective study. 
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TABLES 
Table 1. Patients and tumors characteristics 
Patient 
# Gender 
Age*
 
(years) 
Eye  
side 
Tumor size† (mm) 
TNM-AJCC‡ 
(Stage) 
Primary tumor 
therapy  Height  
Largest basal 
diameter 
1 Man 73 Right   2.9 13.1 T4N0M1 (IV) Proton therapy 
2 Woman 69 Left   3.1 14.2 T2N0M0  (II) Proton therapy 
3 Woman 30 Left   5.8 16.3 T3N0M0 (III) Proton therapy 
4 Man 39 Left   5.8 23.5 T3N0M0 (III) Proton therapy 
5 Woman 20 Left   6.8 15.6 T3N0M0 (III) Proton therapy 
6 Man 74 Right   7.0   7.0 T3N0M0 (III) Enucleation 
7 Man 56 Left   9.0 19.0 T3N0M0 (III) Proton therapy 
8 Woman 72 Right 11.4 19.1 T3N0M1 (IV) Proton therapy 
9 Woman 57 Right 12.7 23.3 T3N0M1 (IV) Proton therapy 
10 Woman 71 Left 16.0 15.0 T4N0M0 (III) Enucleation 
*At diagnosis of primary tumor. 
†Tumor size of tumors treated by proton therapy cannot be compared to tumor size of 
enucleation, as the height and largest basal diameter were measured by ultrasound and 
preoperative transillumination respectively in the former and derived from the histo-
pathology report in the latter. 
‡AJCC = American Joint Cancer Committee Classification. 
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Table 2. PET and MRI imaging findings. 
Patient 
Number of 
MRI lesions 
Number of 
PET lesions 
Number of lesions seen 
both on PET & MRI  (%) 
Number of small-sized* 
lesions (mean [range], cm) 
1 2 1 1 (50%)   2 (0.9 [0.8–1.0]) 
2 4 3† 2 (50%)   3 (0.8 [0.5–1.0]) 
3 2 2   2 (100%) 0 (–) 
4 41 18 18 (44%)   20 (0.7 [0.3–1.1]) 
5 2 2† 1 (50%)   2 (0.9 [0.8–0.9]) 
6 26 4 4 (15%) 21 (0.5 [0.5–1.1]) 
7 3 3   3 (100%)   2 (0.8 [0.8–0.8]) 
8 4 2† 1 (25%)   3 (0.4 [0.4–0.4]) 
9 8 2† 1 (13%)   7 (0.5 [0.3–0.8]) 
10 12 1 1 (8%)   11 (0.5 [0.4–1.0]) 
Total 104 38 34 (33%) 71 ([0.3–1.1]) 
*Defined as size < 1.2 cm, which corresponds to twice the PET/CT spatial resolution 
[22]. 
†One PET lesion not visible on MRI.  
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FIGURE CAPTIONS 
Figure 1. Lesion detectability according to imaging modality and lesion size. The vast 
majority of small lesions <1.2 cm, were only visualized by MRI imaging, while the 
larger lesions ≥1.2 cm were mostly visualized by both, MRI and PET. A few lesions 
were only detected on PET 
 
Figure 2. FDG PET, PET/CT fusion, unenhanced CT and MRI transaxial images of two 
patients: (A) A 78-year-old man with several lesions detected on both PET and MRI 
(arrows) and several smaller lesions detected on MRI only (arrowhead) showing hyper-
signal on T1-weighted fat-suppressed gradient-echo (TR 3.7ms, TE 1.6ms, flip angle 
12°); (B) A 33-year-old woman with one 8-mm lesion detected on both PET and MRI 
(arrow) showing an hypersignal on unenhanced T1-weighted spoiled gradient-echo in-
phase (TR 167ms, TE 4.8ms, flip angle 70°) and out-phase (TR 167ms, TE 2.4ms, flip 
angle 70°) 
 
Figure 3. Boxplot of the lesion to liver standardized uptake value (SUV) ratio, which is 
significantly lower for smaller lesions (<1.2 cm) as compared to larger lesions (≥1.2 
cm) (P<0.0001) 
 
Figure 4. Plot of the standardized uptake value (SUV) of the lesion-to-liver SUV ratio 
vs. MRI lesion size for lesions visible on both modalities. There was a significant cor-
relation between lesion-to-liver SUV ratio and lesion size, even above twice the 
PET/CT resolution (y=0.79+0.44·x, r = 0.81, P<0.0001). Note that 8 lesions smaller 
than twice the PET/CT resolution (1.2 cm, dashed line) were also detected on PET/CT 
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Figure 5. Boxplot of the ratio of lesion standardized uptake value (SUV) to liver paren-
chyma SUV according to visualization by MRI+PET or PET alone. The lesion-to-liver 
SUV ratio of lesions visible by both modalities (MRI+PET) was significantly higher 
than unity (P<0.0001) 
 
Figure 6. Boxplot of the lesion size according to visualization by MRI+PET or MRI 
alone. The diameter of lesions visible by both modalities (MRI+PET) was significantly 
larger than lesions visible only by MRI (P<0.0001) 
 
 Figure 7. Variation in lesion-to-liver standardized uptake value (SUV) ratio between 
baseline (PET 1) and follow-up study (PET 2) according to change in lesion size as 
measured by MRI (no change vs. increase in size) for patients with lesions visible on 
both FDG-PET and MRI at baseline (6 patients, 30 lesions in total) 
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